Our results showed that the type of neoadjuvant systemic therapy was driven by tumor subtype: chemotherapy with anti-HER2 agent was delivered to 75.0% of HER2+/HR+ and to 93.9% of HER2+/HR-negative patients; only chemotherapy to 89.1% of HER2-negative/HR+ and to 100% of triple negative patients (Table 5). This evidence concerns the gene ERBB2 and neoplasm.